NAS:UTHR (USA)
Business Description
United Therapeutics Corp
NAICS : 325412
SIC : 2834
1040 Spring Street, Silver Spring, MD, USA, 20910
Description
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.82 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | 0.92 | |||||
| Interest Coverage | 43.98 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 7.44 | |||||
| Beneish M-Score | -2.46 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -1.2 | |||||
| 3-Year EBITDA Growth Rate | -8.7 | |||||
| 3-Year EPS without NRI Growth Rate | -9.1 | |||||
| 3-Year FCF Growth Rate | -9.2 | |||||
| 3-Year Book Growth Rate | 11.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 13.63 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 10.55 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.19 | |||||
| 9-Day RSI | 34.62 | |||||
| 14-Day RSI | 39.9 | |||||
| 6-1 Month Momentum % | 17.64 | |||||
| 12-1 Month Momentum % | 15.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.1 | |||||
| Quick Ratio | 7.83 | |||||
| Cash Ratio | 6.8 | |||||
| Days Inventory | 283.89 | |||||
| Days Sales Outstanding | 37.91 | |||||
| Days Payable | 11.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.1 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 93.41 | |||||
| Operating Margin % | 49.66 | |||||
| Net Margin % | 35.27 | |||||
| ROE % | 15.83 | |||||
| ROA % | 12.15 | |||||
| ROIC % | 23.85 | |||||
| ROC (Joel Greenblatt) % | 100.17 | |||||
| ROCE % | 16.89 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 16.78 | |||||
| Forward PE Ratio | 13.04 | |||||
| PE Ratio without NRI | 16.78 | |||||
| Shiller PE Ratio | 21.1 | |||||
| Price-to-Owner-Earnings | 23.08 | |||||
| PS Ratio | 5.93 | |||||
| PB Ratio | 2.33 | |||||
| Price-to-Tangible-Book | 2.36 | |||||
| Price-to-Free-Cash-Flow | 16.25 | |||||
| Price-to-Operating-Cash-Flow | 13.65 | |||||
| EV-to-EBIT | 10.47 | |||||
| EV-to-Forward-EBIT | 8.55 | |||||
| EV-to-EBITDA | 9.87 | |||||
| EV-to-Forward-EBITDA | 8.19 | |||||
| EV-to-Revenue | 4.83 | |||||
| EV-to-Forward-Revenue | 4.51 | |||||
| EV-to-FCF | 13.25 | |||||
| Price-to-Projected-FCF | 1.4 | |||||
| Price-to-Median-PS-Value | 1.52 | |||||
| Price-to-Graham-Number | 1.33 | |||||
| Price-to-Net-Current-Asset-Value | 6.91 | |||||
| Price-to-Net-Cash | 9.79 | |||||
| Earnings Yield (Greenblatt) % | 9.55 | |||||
| Forward Rate of Return (Yacktman) % | 24.27 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:UTHR
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,788.7 | ||
| EPS (TTM) ($) | 13.21 | ||
| Beta | 0.44 | ||
| Volatility % | 46.17 | ||
| 14-Day RSI | 39.9 | ||
| 14-Day ATR ($) | 7.364127 | ||
| 20-Day SMA ($) | 230.596 | ||
| 12-1 Month Momentum % | 15.45 | ||
| 52-Week Range ($) | 158.38 - 245.48 | ||
| Shares Outstanding (Mil) | 45.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
United Therapeutics Corp Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||